Financial Performance - The company reported total revenue of RMB 1,399,808,311.93 for Q1 2024, a decrease of 37.76% compared to RMB 2,249,034,497.62 in the same period last year[10]. - Net profit attributable to shareholders was RMB 281,970,252.06, down 55.27% from RMB 630,346,004.43 year-on-year[10]. - The net profit after deducting non-recurring items was RMB 253,974,228.11, reflecting a 58.88% decline compared to RMB 617,637,901.61 in the previous year[10]. - Basic and diluted earnings per share were both RMB 0.76, down 55.81% from RMB 1.72 in the same period last year[10]. - Total revenue for Q1 2024 was approximately ¥1.40 billion, a decrease of 37.76% compared to ¥2.25 billion in Q1 2023, primarily due to the impact of large orders in the same period last year[18]. - Operating profit decreased to RMB 294.69 million, a decline of 58.5% compared to RMB 709.95 million in the prior period[38]. - Net profit for the reporting period was RMB 279.53 million, down 55.5% from RMB 627.89 million in the previous period[40]. - Total revenue for the reporting period was RMB 1.40 billion, down 37.8% from RMB 2.25 billion in the previous period[38]. - The company reported a net loss attributable to the parent company of RMB 281,971,000 in Q1 2024, compared to a profit of RMB 630,346,000 in Q1 2023[47]. Revenue Breakdown - Revenue from small molecule business reached RMB 1,223,000,000, with a year-on-year growth of 26.58% after excluding last year's large order impact[13]. - Revenue from emerging businesses was RMB 176,000,000, down 29.30% year-on-year due to the ongoing impact of the domestic investment environment[13]. - Cash received from sales of goods and services was approximately ¥1.74 billion, down 36.76% from ¥2.76 billion in the previous year, influenced by large order repayments from last year[18]. Costs and Expenses - Total costs for Q1 2024 were approximately ¥1.14 billion, down 27.27% from ¥1.57 billion in Q1 2023, mainly due to the decline in revenue[18]. - Sales expenses increased by 31.95% to approximately ¥44.62 million, reflecting continued investment in market expansion and sales activities[18]. - The company reported a significant increase in tax and additional charges, which rose by 374.77% to approximately ¥41 million, attributed to export tax rebates[18]. - Research and development expenses for the period were RMB 169.44 million, an increase from RMB 162.10 million in the previous period[38]. - Research and development expenses for Q1 2024 were RMB 169,442,000, slightly higher than RMB 162,097,000 in Q1 2023[47]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 19,841,423,232.54, a slight increase of 0.38% from RMB 19,767,158,652.70 at the end of the previous year[10]. - Total current assets decreased to RMB 12.11 billion from RMB 12.35 billion, primarily due to a reduction in trading financial assets[31]. - The company reported a total liability of RMB 2.23 billion, slightly down from RMB 2.26 billion at the beginning of the period[35]. - The company’s total equity as of March 31, 2024, was RMB 17,606,958,000, an increase from RMB 17,509,979,000 at the end of the previous year[55]. Cash Flow and Investments - Net cash flow from operating activities for the reporting period was RMB 490,666,474.36, significantly lower than RMB 1,303,525,263.66 in the previous period[44]. - Cash and cash equivalents at the end of Q1 2024 totaled RMB 4,774,669,819.21, down from RMB 5,379,198,112.41 at the end of the previous year[45]. - The cash flow from investing activities showed a net outflow of RMB 284,603,126.59, compared to a net outflow of RMB 327,218,213.85 in the previous period[44]. - The company experienced a foreign exchange gain of RMB 15,685,123.62 during the reporting period, contrasting with a loss of RMB 15,286,791.15 in the previous period[45]. - The company experienced a net cash outflow from investing activities of RMB 284,603 thousand in Q1 2024, compared to RMB 327,218 thousand in Q1 2023[59]. Share Repurchase and Capital Management - The company repurchased shares, resulting in cash payments of approximately ¥218.69 million, marking a new strategy in capital management[18]. - The company plans to repurchase shares with a total fund amount not less than RMB 600 million and not exceeding RMB 1.2 billion, with a repurchase price not exceeding RMB 157 per share[29]. - The financing activities resulted in a net cash outflow of RMB 218,690 thousand in Q1 2024, with share repurchase payments amounting to RMB 213,367 thousand[59]. Project Development - The company confirmed 30 small molecule commercialization projects and 148 clinical stage projects, including 41 in Phase III[13].

Financial Performance - In 2023, Asymchem Laboratories achieved a total revenue growth of 23.67% year-on-year, excluding the impact of large orders[7]. - The company's revenue for the year ended December 31, 2023, was approximately RMB 7,781,436 thousand, a decrease of 23.94% compared to RMB 10,230,186 thousand for the year ended December 31, 2022[18]. - Gross profit for the reporting period was approximately RMB 3,959,636 thousand, down 18.06% from RMB 4,832,588 thousand in the previous year[18]. - Net profit attributable to shareholders for the reporting period was approximately RMB 2,268,811 thousand, a decline of 31.28% from RMB 3,301,635 thousand in the prior year[18]. - The gross margin for the reporting period improved to 50.89%, compared to 47.24% in the previous year[19]. - Adjusted net profit attributable to shareholders was RMB 2,302.09 million, a decrease of 23.23% compared to 2022[80]. - The company reported a significant increase in revenue, achieving a total of $1.2 billion for the fiscal year, representing a 15% year-over-year growth[165]. - The company reported a 5% increase in gross margin, reaching 45% for the fiscal year[165]. Business Growth and Development - Revenue from small molecule CDMO business grew by 75.56% year-on-year, indicating strong collaboration with multinational pharmaceutical companies[7]. - The company celebrated its 25th anniversary in 2023, marking significant commercial breakthroughs and major orders in the small molecule CDMO sector[7]. - The company has increased its production capacity in China, including commercial production capabilities for peptides and ADCs, to meet the demands of emerging businesses[13]. - The company reported a significant increase in employee count from 3,840 at the end of 2019 to 9,788 currently, reflecting its growth trajectory[16]. - The company aims to expand its global presence and is optimistic about the recovery of domestic markets and the growth of emerging businesses[13]. - The company aims to enhance operational efficiency and reduce costs while expanding its market presence in Europe and Japan[24]. - The company aims to diversify its multinational pharmaceutical client base and has made significant breakthroughs in the Japanese market after years of penetration[36]. - The company has established long-term partnerships with 16 out of the top 20 global pharmaceutical companies, demonstrating strong customer loyalty[132]. Research and Development - Continuous production technology and synthetic biology technology have been developed into comprehensive platforms for external technology output, enhancing efficiency and reducing costs[9]. - The company is prioritizing the advancement of its R&D platform to maintain its leading technological position in the industry[9]. - R&D expenditure exceeded RMB 707.86 million, accounting for 9.10% of total revenue, with plans for continued investment in R&D[61]. - The establishment of the biopharmaceutical technology center (CBTI) in Shanghai aims to enhance R&D capabilities and improve process development[56]. - The company has published 41 research papers in leading international journals, with 14 papers having an impact factor exceeding 10[60]. - The company is committed to continuous R&D investment to strengthen its technology-driven approach and maintain its competitive edge in the CDMO sector[137]. Market Trends and Challenges - The global innovation drug development landscape faced challenges in 2023, impacting the entire CXO industry[6]. - Asymchem's strategic deployment has strengthened its capabilities despite the pressures from market uncertainties[6]. - The company is currently conducting 356 clinical research projects, with 123 in Phase II or later[53]. - The company faces potential risks including major innovative drug recalls, operational challenges in clinical projects, and core technical personnel turnover[149]. Operational Efficiency and Cost Management - The company aims to maximize the utilization of newly added production capacity while minimizing raw material waste and reducing operating costs[72]. - Sales costs for 2023 were RMB 3,821.80 million, a decrease of 29.19% compared to RMB 5,397.60 million in 2022, attributed to improved gross margins and strict cost control measures[84]. - The overall gross margin increased by 3.65% to 50.92% in 2023, driven by a higher gross margin from commercial projects and effective cost management[86]. - The company emphasizes optimizing profitability by improving the gross margin of its small molecule CDMO business and controlling production costs through efficiency and management[145]. Strategic Initiatives - The company is actively seeking investments to enrich its service offerings and expand its overseas presence, focusing on commercial production for multinational companies[141]. - The company plans to enhance its delivery capabilities and expand overseas markets by strengthening management and operational systems[146]. - The company aims to deepen relationships with existing clients while expanding its global customer base, particularly targeting small and medium-sized innovative pharmaceutical companies[139]. - The company is focused on diversifying into new drug categories and service types, including biopharmaceutical CDMO services and clinical research[140]. Corporate Governance and Management - The management team has an average of over 20 years of experience in their respective fields, contributing to stable governance and strategic direction[136]. - Zhang Da serves as the Chief Financial Officer and Chief Operating Officer, responsible for financial operations and investment activities[153]. - The supervisory board consists of three members, including two shareholder representatives and one employee representative[162]. Dividend and Shareholder Information - The company plans to distribute a final dividend of RMB 1.80 per share, totaling approximately RMB 664,080,355.80, subject to shareholder approval[18]. - The board proposed a profit distribution plan for 2023, recommending a dividend of RMB 18.00 per 10 shares of common stock, totaling approximately RMB 664,080,355.80 (including tax) based on 369,471,533 shares issued[186]. - The proposed profit distribution plan for 2023 is subject to approval at the annual general meeting of shareholders and is expected to be paid within two months after the meeting[186].

Financial Performance - Total revenue for 2023 was RMB 7,781.44 million, a decrease of 23.94% compared to RMB 10,230.19 million in 2022[6] - Gross profit for 2023 was RMB 3,959.64 million, down 18.06% from RMB 4,832.59 million in 2022, with a gross margin of 50.89%, an increase of 3.65% year-on-year[6] - Net profit attributable to shareholders for 2023 was RMB 2,268.81 million, a decline of 31.28% from RMB 3,301.64 million in 2022, resulting in a net profit margin of 29.16%[6] - Adjusted net profit attributable to shareholders was RMB 2,302.09 million, down 23.23% from RMB 2,998.81 million in 2022, with an adjusted net profit margin of 29.58%[6] - The company confirmed 40 commercial projects generating revenue of RMB 5,107.49 million, a decline of 32.51% year-on-year[78] - Net profit decreased by 31.68% from RMB 3,294.63 million in 2022 to RMB 2,250.82 million in 2023, with a net profit margin of 29.16% compared to 32.27% in 2022[94] - Basic and diluted earnings per share fell from RMB 9.00 in 2022 to RMB 6.26 in 2023, reflecting the decline in net profit[95] Revenue Breakdown - Revenue from small molecule CDMO services was RMB 6,605.14 million, with remaining revenue (excluding large orders) of RMB 4,184.62 million, reflecting a year-on-year growth of 25.47%[11] - Revenue from multinational pharmaceutical companies was RMB 4,988.48 million, a decrease of 32.20%, but excluding large orders, revenue increased by 75.56% to RMB 2,567.96 million[12] - Revenue from U.S. customers was RMB 2,846.75 million, showing a significant year-on-year increase of 47.84%[15] - Emerging business segment revenue reached RMB 1,170.20 million, representing a year-on-year growth of 17.79%[11] - Revenue from overseas markets was RMB 6,344.16 million, a decrease of 26.83% year-on-year, but grew by 41.41% after excluding large orders[81] R&D and Innovation - Research and development expenditure exceeded RMB 707.86 million, accounting for 9.10% of total revenue[53] - The company has developed over 2,700 existing engineered enzymes, with more than 1,100 proprietary enzymes, and successfully developed 17 types of enzyme reagent kits for rapid screening[41] - The company has published 41 research papers in leading international journals, with 14 papers having an impact factor exceeding 10[52] - The launch of the Biological Science Technology Center (CBTI) in May 2023 aims to enhance internal R&D capabilities and streamline process development[140] - The company plans to increase R&D investment and establish an iterative development platform to enhance process synthesis design and optimization[153] Market Position and Strategy - The company has established partnerships with 16 of the top 20 multinational pharmaceutical companies, with 8 of these relationships exceeding 10 years[25] - The company aims to deepen service offerings and expand its client base, particularly in the Japanese market, which has shown significant growth in 2023[27] - The company is focusing on enhancing clinical project reserves to ensure long-term growth, with a strategic emphasis on potential blockbuster projects in the clinical III phase[24] - The company aims to leverage its advanced R&D platforms and strong production capabilities to further enhance its market leadership in the small molecule CDMO sector[137] - The company is actively diversifying into areas such as macromolecular drugs, drug formulation services, and clinical research services, which are expected to open new growth avenues[145] Operational Efficiency - The company is actively optimizing the process development cycle to enhance delivery quality and efficiency, with multiple patents currently under application[49] - The company aims to enhance delivery capabilities and expand overseas markets by accelerating the development of emerging services, focusing on small nucleic acids, peptides, and ADC commercialization production capacity[152] - The company is focusing on creating potential technological advantages through the development of an AI protein design platform[43] - The company has expanded its lipid nanoparticle technology platform and is continuously developing various complex formulation technology platforms, including nasal sprays and aerosol inhalation solutions[36] - The company is committed to balancing economic benefits with social and environmental responsibilities, ensuring a transparent governance structure[72] Corporate Governance - The company has adopted corporate governance principles and believes it has complied with all except one guideline during the reporting period[162] - The roles of the chairman and CEO are held by the same individual, which the board believes does not compromise the balance of power within the company[163] - The board emphasizes high standards of corporate governance to protect shareholder interests and enhance corporate value[164] - The company has confirmed compliance with the standard code for securities trading throughout the fiscal year ending December 31, 2023[166] - The board proposed a final dividend of RMB 18.00 per 10 shares for the year ending December 31, 2023, totaling approximately RMB 664,080,355.80 (including tax), compared to RMB 656,437,642.20 in 2022[176]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821) 二零二三年第三季度報告 本公告乃由凱萊英醫藥集團（天津）股份有限公司（「公司」或「本公司」，連同其 附屬公司「本集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09條及第13.10B條以及證券及期貨條例（香港法例第571章）第XIVA部項下的 內幕消息條文（定義見上市規則）而作出。 茲載列本公司在深圳證券交易所網站刊發的《凱萊英醫藥集團（天津）股份有限公 司二零二三年第三季度報告》，僅供參閱。本公司二零二三年第三季度報告（「二 零二三年第三季度報告」）以中、英文雙語編製。如兩個版本有任何不相符之處， 應以中文版本為準。 本公司董事（「董事」）會（「董事會」）提醒本公司股東及潛在投資者，本公告所載 ...

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 4,595,708, a decrease of 8.71% compared to RMB 5,034,065 for the same period in 2022[18]. - Net profit attributable to shareholders was RMB 1,686,368, a decrease of 3.09% from RMB 1,740,095 in the prior year, with a net profit margin of 36.7%[18]. - Basic earnings per share for the first half of 2023 were RMB 4.65, down from RMB 4.75 in the previous year[18]. - The total revenue for the reporting period reached RMB 4.596 billion, with a year-on-year growth of 32.71% after excluding large orders[22]. - The company confirmed revenue from 34 commercial projects totaling RMB 3.209 billion, with a year-on-year growth of 60.50% after excluding large orders[28]. - The net profit for the first half of 2023 was RMB 1,686,368 thousand, compared to RMB 1,740,095 thousand in the same period of 2022, indicating a decrease of about 3.09%[179]. - Revenue from a single major customer for the six months ended June 30, 2023, was approximately RMB 2,225,728,303, down from RMB 3,212,304,000 for the same period in 2022, indicating a decrease of about 30.73%[192]. Profitability and Margins - Gross profit increased to RMB 2,426,685, representing a gross margin of 52.8%, up from 46.9% in the previous year[18]. - Adjusted net profit attributable to shareholders rose to RMB 1,636,426, reflecting a 6.44% increase from RMB 1,537,478 in the previous year[18]. - The overall gross margin increased by 6 percentage points to 52.85%, driven by improved margins on commercial projects and effective cost management[64]. - The adjusted net profit attributable to shareholders for the same period was RMB 1,636,426 thousand, compared to RMB 1,537,478 thousand in 2022, resulting in an adjusted net profit margin of 35.61%, up from 30.54%[85]. Revenue Breakdown - Revenue from small molecule CDMO business was RMB 4.064 billion, with a year-on-year growth of 32.41% after excluding large orders[22]. - Emerging business revenue reached RMB 528 million, showing a year-on-year increase of 34.33%[22]. - Revenue from US market customers was RMB 3.329 billion, with a year-on-year growth of 44.17% after excluding large orders[23]. - Revenue from clinical and pre-clinical CDMO solutions was RMB 854,544,000 for the first half of 2023, down from RMB 966,407,000 in 2022, reflecting a decrease of approximately 11.56%[197]. - Revenue from commercial stage CDMO solutions was RMB 3,209,311,000, a decrease of 12.59% from RMB 3,670,602,000 in the previous year[197]. Research and Development - The company invested RMB 323 million in R&D during the first half of 2023, representing a year-on-year increase of 22.84%[42]. - Research and development expenses rose by 23% to RMB 323.5 million, reflecting the company's commitment to technological innovation and core technology development[69]. - The company is committed to strengthening its R&D platform, utilizing iterative computing capabilities to support cross-departmental collaboration in process, engineering, and equipment[104]. Market and Business Strategy - The company is actively exploring new business areas, including chemical macromolecule CDMO and clinical CRO services[21]. - The company aims to expand its market influence by enhancing collaboration with multinational pharmaceutical companies and increasing penetration in the Japanese market[100]. - The business plan for 2023 focuses on deepening relationships with large clients, exploring small and medium-sized clients, and expanding into European and Japanese markets[99]. - The company is committed to a technology-driven strategy, emphasizing the continuous growth of its core small molecule CDMO business while developing strategic emerging industries[99]. Operational Efficiency - The company aims to optimize production processes continuously to reduce costs and improve efficiency, ensuring stable product quality and supply[20]. - The company has developed a modular solution for automated control of temperature, pressure, and pH, significantly improving production efficiency[45]. - The company is focused on integrating digital platforms and predictive capabilities to optimize production processes and enhance operational efficiency[43]. Financial Position - Cash and bank balances increased by RMB 1,752 million, a growth of 33%, mainly due to net cash inflow from operating activities of RMB 2,253 million[73]. - The asset-liability ratio decreased from 13.9% at the end of 2022 to 12.5% by June 30, 2023[78]. - Total assets increased by 4% to RMB 5,039,078 thousand, primarily due to the conversion of construction in progress[80]. - The company's total equity reached RMB 16,791,971 thousand, an increase from RMB 15,695,003 thousand as of December 31, 2022, representing a growth of approximately 6.96%[177]. Risks and Challenges - The company acknowledges potential risks related to the market exit or recall of major innovative drugs, emphasizing the need for proactive risk management[108]. - The company is aware of the uncertainties in the commercialization prospects of its clients' drugs, which may lead to lower-than-expected sales[109]. - The company faces risks related to international trade tensions and has planned effective backup measures to mitigate potential adverse effects[113]. Employee and Governance - The company introduced 73 senior talents during the reporting period, including 32 PhDs and 31 individuals with overseas pharmaceutical experience[49]. - The company emphasizes a "people-oriented" approach, focusing on employee rights and welfare, and has implemented stock incentive plans to boost employee motivation[53]. - The group had 9,145 employees as of June 30, 2023, with competitive compensation packages based on performance and market rates[157]. Shareholder Information - The board does not recommend the payment of an interim dividend for the six months ending June 30, 2023[124]. - The company has granted a total of 3,327,450 restricted A shares under the A-share equity incentive plan as of June 30, 2023, representing approximately 0.90% of the total issued shares[143].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 截至二零二三年六月三十日止六個月 中期業績公告 凱萊英醫藥集團（天津）股份有限公司（「本公司」、「公司」、「凱萊英」）董事（「董 事」）會（「董事會」）欣然公佈本公司及其附屬公司（統稱「本集團」、「我們」）截至 二零二三年六月三十日止六個月（「報告期」）的未經審計綜合中期業績，連同截至 二零二二年六月三十日止六個月（「同期」）之比較數字。除非在本公告內另有界 定，否則本公告內詞彙具有招股章程所界定的相同涵義。 本公告所載若干金額及百分比數字已作四捨五入調整，或約整至小數點後一位或 兩位。任何表格、圖表或其他地方所列總數與數額總和之間如有任何差異，皆因 約整所致。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821) 2023年第一季度報告 本公告乃由凱萊英醫藥集團（天津）股份有限公司（「公司」或「本公司」，連同其 附屬公司「本集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09條及第13.10B條以及證券及期貨條例（香港法例第571章）第XIVA部項下的 內幕消息條文（定義見上市規則）而作出。 以下為本公司的2023年第一季度報告。本季度報告所載之財務數據根據中國企業 會計準則編製。本2023年第一季度報告未經審計。 本公司2023年第一季度報告以中、英文雙語編製。如兩個版本有任何不相符之 處，應以中文版本為準。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 ...

Financial Performance - In 2022, Asymchem Laboratories achieved revenue of approximately RMB 10,230,186 thousand, an increase of 120.9% compared to RMB 4,632,121 thousand in the previous year[8]. - Gross profit for the year was approximately RMB 4,832,588 thousand, up 135.8% from RMB 2,049,725 thousand in 2021[8]. - Net profit attributable to shareholders was approximately RMB 3,301,635 thousand, representing a 208.8% increase from RMB 1,069,274 thousand in the prior year[8]. - Adjusted net profit attributable to shareholders, excluding IFRS adjustments, was approximately RMB 2,998,806 thousand, a 167.0% increase from RMB 1,122,997 thousand in 2021[8]. - Revenue increased significantly from RMB 1,822,787 thousand in 2018 to RMB 10,230,186 thousand in 2022, representing a compound annual growth rate (CAGR) of approximately 46.5%[9]. - Net profit attributable to shareholders rose from RMB 428,202 thousand in 2018 to RMB 3,301,635 thousand in 2022, reflecting a CAGR of about 56.5%[9]. - Gross profit margin improved from 46.0% in 2018 to 47.2% in 2022, indicating enhanced operational efficiency[9]. - The total assets increased from RMB 3,188,076 thousand in 2018 to RMB 18,239,273 thousand in 2022, showcasing robust growth in the company's asset base[9]. - The company achieved total revenue of RMB 10.23 billion in 2022, representing a year-on-year growth of 120.9%[31]. - The small molecule CDMO business generated revenue of RMB 9.23 billion, up 118.1% year-on-year, while emerging services revenue reached RMB 993 million, growing by 150.3%[31]. - Revenue from overseas markets amounted to RMB 8.67 billion, reflecting a year-on-year increase of 117.2%, with the Americas growing by 112.7% and the Asia-Pacific region (excluding China) increasing by 169.9%[35]. - The company's net profit attributable to shareholders reached RMB 3.30 billion, a significant increase of 208.8%, with a net profit margin of 32.3%[36]. - The gross profit margin improved to 47.2%, up 3.0 percentage points from 2021, driven by economies of scale and high capacity utilization[36]. Business Growth and Strategy - The company reported a significant growth in emerging business revenue, reaching nearly RMB 1 billion in 2022, a year-on-year increase of about 150%[6]. - Asymchem's strategic planning continues to evolve, focusing on technology-driven growth and exploring new business models to enhance revenue contributions[7]. - The company aims to maintain its leading position in small molecule CDMO while injecting new growth engines through emerging business developments[7]. - The company has achieved over 33% application rate of continuous reaction technology and biocatalysis technology in late-stage clinical projects[15]. - The company has expanded its small molecule CDMO service capabilities to include new drug categories such as peptides, oligonucleotides, monoclonal antibodies (mAb), antibody-drug conjugates (ADC), and mRNA[20]. - The company has established a comprehensive biocatalysis technology platform with over 2,400 enzymes in its library, 40% of which are proprietary intellectual property[21]. - The company’s fermentation production capacity reaches 10,000L per week, providing high-quality production capabilities from milligrams to tons[21]. - The company has provided process development and production services to over 800 global clients since 2016, including several blockbuster drugs with sales exceeding $1 billion[23]. - The company has established strong partnerships with 15 of the top 20 global pharmaceutical companies, maintaining long-term collaborations with eight of them for over ten years[28]. - The company is expanding its CDMO capabilities into new business areas such as peptides, oligonucleotides, and biologics, enhancing its service offerings[25]. Research and Development - The company invested RMB 708.9 million in R&D, marking an 83.0% increase and accounting for 6.9% of total revenue[68]. - The company has a workforce of over 4,656 scientists and engineers, supporting its advanced R&D platform and driving technological innovation[26]. - The company has achieved a 100% pass rate in 35 official audits by major regulatory agencies since 2011, including FDA and NMPA[27]. - The company has developed a comprehensive operational system that meets the highest global industry standards in R&D, production, quality control, and project management[27]. - The company is committed to enhancing its strategic decision-making through expert advisory committees, including the BSA and BDSA, to drive technological advancement and market expansion[30]. Market Trends and Projections - The global pharmaceutical R&D investment is projected to grow from USD 243.7 billion in 2022 to USD 328.8 billion by 2026, with a CAGR of approximately 7.8%[10]. - The outsourcing ratio of pharmaceutical R&D investment in China is expected to rise from 42.6% in 2022 to 52.2% by 2026, indicating a growing trend in outsourcing services[11]. - The number of pharmaceutical R&D companies in China surged by 43.3% from 522 in 2021 to 792 in 2022, reflecting a shift towards innovation[12]. - The global CDMO market for pharmaceutical R&D services is anticipated to grow from RMB 131.2 billion in 2022 to RMB 336.8 billion by 2026, with a CAGR of approximately 26.6%[13]. Corporate Governance and Leadership - The board consists of nine members, including four executive directors, two non-executive directors, and three independent non-executive directors[115]. - The company has a strong leadership team with extensive experience in various sectors, enhancing its strategic direction and operational efficiency[116][117][118][119][120]. - The board's composition reflects a balance of executive and independent oversight, ensuring robust governance practices[115]. - The company emphasizes the importance of good corporate governance for enhancing management and protecting overall shareholder interests[200]. - The board believes that the company has complied with the relevant provisions of the corporate governance code during the reporting period, except for clause C.2.1[200]. Sustainability and Compliance - The company is committed to sustainable development by creating low-energy, low-emission, and high-efficiency operational models[15]. - The company emphasizes the importance of environmental policies and has implemented measures to reduce energy consumption and waste[146]. - The company is committed to compliance with environmental, social, and governance regulations, with details to be disclosed in future reports[146]. - The company has not identified any significant non-compliance issues with relevant laws and regulations[146]. Future Outlook - The company has outlined a positive future outlook, projecting a revenue growth of 10-15% for the upcoming fiscal year[123]. - The company aims to deepen relationships with large clients while actively expanding its presence in the European and Japanese markets, focusing on cost control and efficiency improvements in 2023[106]. - The company plans to enhance its small molecule CDMO business and accelerate the development of strategic emerging businesses, leveraging a robust operational management system[106]. - The company is committed to enhancing clinical research services, aiming to establish a strong industry reputation and increase the number of clinical research service orders[110].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或倚賴該 等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 截至2022年12月31日止年度之年度業績公告 凱萊英醫藥集團（天津）股份有限公司（「本公司」、「公司」、「凱萊英」）董事（「董 事」）會（「董事會」）欣然公布本公司及其附屬公司（統稱「本集團」、「我們」）截至 2022年12月31日止年度（「報告期」）的經審計綜合年度業績，連同截至2021年12 月31日止年度（「同期」）之比較數字。本集團於報告期間的綜合財務報表已由審核 委員會審閱及由本公司核數師安永會計師事務所審核。除非本公告另有界定，否 則本公告所用詞彙與本公司日期為2021年11月30日的招股章程（「招股章程」）所 界定者具有相同涵義。 本公告所載若干金額及百分比數字已作四捨五入調整，或約整至小數點後一位或 兩位 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或倚賴該 等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 截至2022年12月31日止年度之年度業績公告 凱萊英醫藥集團（天津）股份有限公司（「本公司」、「公司」、「凱萊英」）董事（「董 事」）會（「董事會」）欣然公布本公司及其附屬公司（統稱「本集團」、「我們」）截至 2022年12月31日止年度（「報告期」）的經審計綜合年度業績，連同截至2021年12 月31日止年度（「同期」）之比較數字。本集團於報告期間的綜合財務報表已由審核 委員會審閱及由本公司核數師安永會計師事務所審核。除非本公告另有界定，否 則本公告所用詞彙與本公司日期為2021年11月30日的招股章程（「招股章程」）所 界定者具有相同涵義。 本公告所載若干金額及百分比數字已作四捨五入調整，或約整至小數點後一位或 兩位 ...